You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗調整醫藥股目標價 看好阿里健康、翰森、中生及昊海生物等
阿思達克 01-29 14:26
花旗發表報告表示,在開放線上處方藥銷售、處方藥流出及線上醫療措施等支持性政策的推動下,預計線上醫療諮詢及藥品銷售增長將進一步加快。互聯網醫療將在未來十年內在中國醫療體系中至關重要,以更好地分配醫療資源,提高效率和透明度,並提高長期商業保險參與度。該行指,行業首選阿里健康(00241.HK),目標價由30元上調至50元。

報告又指,建議重新焦點於大型且有良好的記錄的醫藥股,如翰森製藥(03692.HK)、中生製藥(01177.HK)等,相信集中採購的措施對該等公司影響不大,其中將翰森目標價由50元升至60元;至於醫療器械方面,則看好昊海生物(06826.HK)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account